Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC
Lifileucel monotherapy achieved an objective response rate of 25.6% and durable responses in previously treated advanced nonsquamous NSCLC patients.
In a registrational phase‑2 trial (IOV‑LUN‑202, NCT04614103), 39 patients with metastatic or unresectable nonsquamous NSCLC who had progressed on prior chemotherapy and immune‑checkpoint inhibitors received lifileucel (Amtagvi) monotherapy following non‑myeloablative lymphodepletion and interleukin‑2 support. The objective response rate (RECIST v1.1) was 25.6% (10/39), including 2 complete and 7 partial responses. The disease‑control rate was 71.8%. With a median follow‑up of 25.4 months, the median duration of response was not reached, demonstrating durable disease control. The safety profile was consistent with lymphodepletion and IL‑2, with no new safety signals.
The study indicates a meaningful clinical benefit in a historically hard‑to‑treat population of NSCLC patients who have failed standard therapies, offering a one‑time cellular therapy that yields durable responses and could expand therapeutic options.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT